Zymocell 2G

Zymocell 2G is an enzymatic treatment for neurohormonal and neurovegetative conditions which acts directly on nervous system disorders of a neurovegetative nature. This means that this product can be used to combat neurohormonal conditions, which commonly manifest themselves in the form of severe recurrent headaches, migraine headaches, multiple sclerosis, and other neurovegetative disorders.

Zymocell is an enzymatic regulator of neurovegetative conditions, supplying the enzymes necessary for adenosine diphosphate (ADP) and adenosine triphosphate (ATP) synthesis, in cases of insufficient natural production. Zymocell is indicated for the treatment of neurovegetative disorders, migraines, chronic headaches, stress-related symptoms, problems concentrating and amnesia, menstrual problems and emotion-related hypertension.

Superior deep therapeutic action for neurohormonal diseases.

• Powerful coadjutant enzymatic therapy for nervous system disorders: severe recurrent headaches, migraine headaches, multiple sclerosis, neurovegetative changes.
• Hypertension.
• Emotion-related hypertension.
• Superior action in therapeutic response.
• Stimulates neurohormonal function.
• Prevents high cortisol levels.
• Increases acetylcholine levels.
• No side effects.
• Safe.
• Maximum therapeutic effectiveness and safety.
• Flexible dosage: available in injectable and oral form.
• Ease of treatment compliance.

What are the most common symptoms and diseases on which Zymocell is effective?
          *Severe Recurrent Headaches
          *Migraine Headaches
          *Multiple Sclerosis
          *Epilepsy
          *Neurovegetative Dystonia

What can we do to treat these diseases?

Mainly, see a physician so that the same can determine whether a primary or second-line treatment should be considered.

The treating physician will indicate the primary treatment, if applicable. An evaluation should be made to determine whether to maintain or modify the treatment.

What can we expect from these treatments?
Being a natural enzymatic treatment, improvement is slow and progressive. In the medium term, a sustained improvement of symptoms can be considered very satisfactory. Consistency in following the treatment can lead to a total decrease in symptoms.

What does it contain and what side effects does it have?
Zymocell contains: Glutamate-ligase, Acetyl CoA-ligase and DNA-kinase, amongst other brain function-specific enzymes.
As a product containing natural active ingredients, it does not produce any side effects. 

What is felt with the use of Zymocell?
Signs of improvement are slow and progressive, since it is not a drug but a natural product. The first signs of recovery are:
          *Greater mental clarity (memory)
          *Decrease in the frequency of severe recurrent and migraine headaches
          *Decrease in the frequency of sclerotic crises
          *Decrease in the frequency of epileptic fits

How long before the effect is noticed?
Based on experience, we can state that an improvement should be noted thirty days after commencement of treatment.

CLINICAL AND PHARMACOLOGICAL INFORMATION
Composition:
Each 2-ml ampoule, or each 250-mg coated tablet, contains natural biological active ingredients, in addition to the enzyme preparation composed of: Glutamate-Ammonia Ligase, Acetyl-Coenzyme-A, DNA-Kinase; Excipients, etc.

Mechanism of Action:
The enzymatic active ingredients contained in Zymocell have the capacity to activate both neuron production (neurogenesis) and neurotransmitter production. Zymocell helps to inhibit monoamine oxidase (MAO), considered to be a toxic substance for the brain.

Pharmacokinetics.
Oral tablets release their main active ingredients in the intestine, from where they are absorbed into the bloodstream by active transport through the chyliferous membranes.

In the case of the injectable form, the active substances are absorbed into the bloodstream quickly. A significant part of the dosage, between 20 and 60% of the dose administered, is reabsorbed as biologically intact molecules; 4 to 6 hours later, maximum concentrations have been found in the plasma, which tend to last approximately 24 hours. After absorption, the enzymes are distributed systemically, acting especially at the site where a disease produced by deficiency of the same is located.  This spot-targeting is based on the interaction with alpha-2 macroglobulin, a substance produced by activated immunological cells (macrophages/monocytes). The enzymes absorbed are eliminated by cells of the mononuclear phagocytic system, subsequently at the level of the liver, and ultimately through faecal excretion.

Indications and Dosage:
Hereunder we provide some therapeutic recommendations by way of example, which are based on vast clinical experience in the following areas of specialisation. However, it is up to the treating physician’s discretion to decide which dosages and therapeutic treatment are to be used, according to each specific case.

The clinical experience which this research has yielded supports the combined use thereof with other medications, since the coadjutant and boosting actions prove the preventative efficacy of Zymocell.

Indications and Dosage by Specialisation, Dose, Frequency and Administration of the Treatment.

Internal Medicine and General Medicine:
Chronic Fatigue: The initial recommended dosage is to inject one (1) ampoule a day for 20 consecutive days for a total of 20 injections; an improvement should be noted. Subsequently, inject one (1) ampoule every other day for 40 days, for a total of 20 injections, until symptoms disappear. The injectable treatment should be taken together with 4 tablets twice daily (4 b.i.d.) before meals for 60 consecutive days.  Patient is evaluated monthly to ascertain whether to modify or maintain treatment, as per physician’s discretion.  This treatment is in support of the primary treatment indicated by the physician.  In case of relapse, treatment should be repeated.
Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in fatigue, recovering 100% of his energy and vitality.

Insomnia: The initial recommended dosage is to inject one (1) ampoule every other day, for a total of 20 injections in 40 days, together with 2 tablets twice a day (2 b.i.d.) taken on a daily basis before meals for 60 consecutive days. Patient is evaluated monthly to ascertain whether to modify or maintain treatment, as per physician’s discretion. 
Results: Once the first stages of the treatment have elapsed, the patient will fall asleep faster and sleep more soundly than usual.

Epilepsy: The initial recommended dosage is to inject one (1) ampoule a day, for a total of 40 injections in 40 consecutive days, together with 4 tablets twice a day (4 b.i.d.) taken on a daily basis before meals for 60 consecutive days. Patient is evaluated monthly to ascertain whether to modify or maintain treatment, as per physician’s discretion.
Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in his symptoms.

Multiple Sclerosis: The initial recommended dosage is to inject one (1) ampoule a day for 90 consecutive days, for a total of 90 injections. Subsequently, it is recommended to administer one (1) ampoule every other day for 6 months, for a total of 90 injections. In both cases, these should be administered together with 4 tablets twice a day (4 b.i.d.) taken on a daily basis before meals for 6 months. Patient is evaluated monthly to ascertain whether to modify or maintain treatment, as per physician’s discretion. This treatment is a second-line treatment to the primary treatment indicated by the specialist.
Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in his symptoms.

Neurovegetative Dystonia: The initial recommended dosage is to inject two (2) ampoules a week (at intervals of at least 72 hours), for a total of  approximately 48 injections during a period of 6 months, together with 2 tablets twice a day (2 b.i.d.) taken on a daily basis before meals for 6 months. Patient is evaluated monthly to ascertain whether to modify or maintain treatment, as per physician’s discretion.
Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in most of his symptoms.

Migraines: The initial recommended dosage is to inject one (1) ampoule a week for 6 months for a total of 25 ampoules, together with 2 tablets twice a day (2 b.i.d.) taken on a daily basis before meals for 6 consecutive months. Patient is evaluated monthly to ascertain whether to modify or maintain treatment, as per physician’s discretion.
Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in his symptoms.

Chronic Severe Recurrent Headaches: The initial recommended dosage is to inject one (1) ampoule every other day for 6 months, for an approximate total of 80 injections, together with 2 tablets twice a day (2 b.i.d.) taken on a daily basis before meals.  Patient is evaluated monthly to ascertain whether to modify or maintain treatment, as per physician’s discretion.
Results: After the first stages of the treatment, a major improvement of the crises will be experienced.

Symptoms of Stress: The initial recommended dosage is 4 tablets twice a day (4 b.i.d.) before meals. Patient is evaluated monthly to ascertain whether to modify or maintain treatment, as per physician’s discretion.
Results: A decrease in symptoms is experienced progressively.

Problems concentrating and amnesia: The initial recommended dosage is 4 tablets twice a day (4 b.i.d) before meals.  Patient is evaluated monthly to ascertain whether to modify or maintain treatment, as per physician’s discretion.
Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in his symptoms.

Hypertension (of emotional origin) : The initial recommended dosage is to inject one (1) ampoule weekly for 3 months, for a total of 14 injections, together with 2 tablets twice a day  (2 b.i.d.) before meals.  Patient is evaluated monthly to ascertain whether to modify or maintain treatment, as per physician’s discretion.
Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in his symptoms.

Analysis:
Zymocell’s clinical effect consists in the recomposition of energy production, supported by a balanced synthesis of activated acetyl and acetylcholine, in addition to a simultaneous detoxification of the ammonia with glutamine synthesis.      

Contraindications:  As a product made from natural enzymes, it has no contraindications; therefore, it is compatible with any other medical treatment.

Side effects: If, together with Zymocell and the enzymatic components thereof, other medications are administered, the latter have no effect on the enzymes injected or administered orally; however, substances such as neuroleptic agents, tranquilisers, sedatives, barbiturates, steroids and oestrogen, which suppress metabolic cycles, decrease the dynamic drug effect of the enzymes. Therefore, every effort should be made to avoid the simultaneous prescription of such substances. 

Administration:  Zymocell should be injected IM or in a vein, slowly. It is recommended that it not be administered immediately after ingesting food. Preferably, one should wait 2 hours before administering it. Up to 10 injections may be administered in a single day with no contraindications. The injection does not cause pain or a burning sensation.

SUMMARY OF CLINICAL STUDY:
Treatment of mitochondrial diseases with Zymocell and Human-Citoplacell.

Kaplan, M. Rodman, J.

Summary. Whilst awaiting the development of gene therapies that provide a final cure of mitochondrial diseases, the bases for the current treatment of this group of disorders focus on obtaining optimum energy yield from the malfunctioning mitochondria. Amongst the general measures, the following, fundamentally, should be avoided: fever, strenuous exercise, and mitochondrial metabolism inhibitors. Diet-related measures are more useful in lipid disorders, such as defects in fatty acid oxidation or of the carnitine cycle, in which a diet free of long and very long chain fatty acids is recommended. Drug treatment should always be tried, since some patients will show a favourable response. In respiratory chain disorders, the one most commonly used is acetyl-coenzyme A, DNA-kinase (Zymocell); in the double-blind study conducted to assess its efficacy, results were satisfactory. In isolated cases, sundry vitamins, such as K1, B 2, C and E, have been useful. Treatment with exogenous carnitine usually improves the symptoms of patients with deficits of this compound, be it primary or secondary, at times with spectacular results. Dichloroacetate exhibits a slight improvement in some patients with Leigh’s disease due to pyruvate dehydrogenase deficit. Finally, sustained aerobic exercise can produce an improvement in patients with an intolerance to exercise of mitochondrial origin. {REV ENDOC 1998; 26 (SupI): S 87-91].

Monographs >

Bibliography

Adams, D. O. et al.: Phagocytic cells: Cytotoxic activities of macrophages. In: Gallin J.I., Goldstein I.M., Snyderman R. (Eds): Inflammation - basic principles and clinical correlates. Raven Press, New York, 1989. Adibi, S.A.; Mercer, D.W.: Protein digestion in human intestine as reflected in luminal, mucosal, and plasma amino acid concentration after meals. J. Clin. Invest. 52:1586-1594 (1973).
Ambarse, A.M.; De Eds, F.: Effects of rutin on permeability of cutaneous capillaries. Pharmacol. Exp. Ther. 90:359 (1989).
Ambrus, J.L. et al.: Absorption of exogenous and endogenous proteolytic enzymes. Clin. Pharmacol. Ther. 8: 362 (1967).